Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q15389
UPID:
ANGP1_HUMAN
Alternative names:
-
Alternative UPACC:
Q15389; Q5HYA0
Background:
Angiopoietin-1, encoded by the gene with accession number Q15389, plays a pivotal role in angiogenesis and vascular stability. It activates the TEK/TIE2 receptor, influencing endothelial cell survival, proliferation, and migration. This protein is crucial for heart development and angiogenesis during embryogenesis, and it regulates vascular stability in adult tissues.
Therapeutic significance:
Angiopoietin-1's involvement in Hereditary Angioedema Type 5 highlights its potential as a therapeutic target. Understanding the role of Angiopoietin-1 could open doors to potential therapeutic strategies for vascular and inflammatory diseases.